Despite the fact that overall prognosis for BRAFV600E mutant metastatic CRC is worse as compared to BRAF-wild-type CRC, the assessment of the BRAF V600E status should be mandatory in future adjuvant trials with the prospect to be incorporated in the clinical practice. Here, BRAF is linked to colorectal carcinoma.